As a primary prevention of atherosclerosis and cardiovascular diseases. As part of the complex therapy of atherosclerosis, coronary heart disease, hypertension; for secondary prevention of myocardial infarction as an addition to standard treatment methods (for example, statins, antiplatelet agents, beta-blockers, ACE inhibitors); for hypertriglyceridemia in addition to diet therapy, if the latter is not effective enough.
Epadol NEO Composition
active substance: 1 capsule contains 1000 mg of ethyl esters of omega-3 acids, which include:
eicosapentaenoic acid 300 mg;
docosahexaenoic acid 200 mg;
other fatty acids 498 mg;
d-α-tocopherol (vitamin E) 2 mg;
Epadol NEO excipients: gelatin, glbcerin (in the gelatin capsule shell).
Epadol NEO Dosage form
Basic physical and chemical properties: soft gelatin capsules from light yellow to dark yellow, oval in shape, with a seam. The content of the capsule is an oily liquid from light yellow to dark yellow in color with a specific odor.
Omega-3 triglycerides, including other esters and acids. ATX code С10А Х06.
The omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are essential fatty acids.
The drug actively affects blood plasma lipids, reducing the level of triglycerides, low and very low density lipoproteins (VLDL). The drug affects hemostasis and reduces the risk of thrombus formation by affecting the aggregation ability of platelets; moderately lowers blood pressure.
The normalization of the blood lipid spectrum also occurs due to a decrease in the synthesis of triglycerides in the liver, since EPA and DHA inhibit the esterification of other fatty acids, as well as due to a decrease in the amount of free fatty acids (the amount of peroxisome β-oxidation of fatty acids increases), which are involved in the synthesis of triglycerides … A decrease in triglyceride synthesis leads to a decrease in VLDL levels.
Alpha-tocopherol is an antioxidant that prevents the oxidation of polyunsaturated fatty acids.
Pharmacokinetic data are not available.
As a primary prevention of atherosclerosis and cardiovascular diseases.
As part of the complex therapy of atherosclerosis, coronary heart disease, arterial hypertension; for secondary prevention of myocardial infarction as an addition to standard treatment methods (for example statins, antiplatelet agents, beta-blockers, ACE inhibitors); with hypertriglyceridemia, in addition to diet therapy, if the latter is not effective enough.
Hypersensitivity to any component of the drug. Exacerbation of chronic cholecystitis, exacerbation of chronic pancreatitis, exacerbation of diseases of the hepatobiliary system, cholelithiasis, pathological conditions, including hemorrhagic syndrome.